S.L. Topalian, F.S. Hodi, J.R. Brahmer, S.N. Gettinger, D.C. Smith, D.F. McDermott et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med 366(26), 2443–2454 (2012)
Article CAS PubMed PubMed Central Google Scholar
M.A. Postow, M.D. Hellmann, Adverse events associated with immune checkpoint blockade. N. Engl. J. Med 378(12), 1165 (2018)
R. Barroso-Sousa, W.T. Barry, A.C. Garrido-Castro, F.S. Hodi, L. Min, I.E. Krop et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol 4(2), 173–182 (2018)
E. Araki, A. Goto, T. Kondo, M. Noda, H. Noto, H. Origasa et al. Japanese clinical practice guideline for diabetes 2019. Diabetol Int 11(3), 165–223 (2020)
Article PubMed PubMed Central Google Scholar
A.M. Stamatouli, Z. Quandt, A.L. Perdigoto, P.L. Clark, H. Kluger, S.A. Weiss et al. Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors. Diabetes. 67(8), 1471–80. (2018)
Article CAS PubMed PubMed Central Google Scholar
S. Yano, K. Ashida, R. Sakamoto, C. Sakaguchi, M. Ogata, K. Maruyama et al. Human leucocyte antigen DR15, a possible predictive marker for immune checkpoint inhibitor-induced secondary adrenal insufficiency. Eur. J. Cancer. 130, 198–203 (2020)
Article CAS PubMed Google Scholar
T. Kobayashi, S. Iwama, D. Sugiyama, Y. Yasuda, T. Okuji, M. Ito et al. Anti-pituitary antibodies and susceptible human leukocyte antigen alleles as predictive biomarkers for pituitary dysfunction induced by immune checkpoint inhibitors. J. Immunother. Cancer 9(5), e002493 (2021)
Article PubMed PubMed Central Google Scholar
H. Inaba, H. Ariyasu, H. Iwakura, C. Kurimoto, K. Takeshima, S. Morita et al. Distinct clinical features and prognosis between persistent and temporary thyroid dysfunctions by immune-checkpoint inhibitors. Endocr. J. 68(2), 231–241 (2021)
Article CAS PubMed Google Scholar
K.E. King, P.M. Ness, H.G. Braine, K.S. Armstrong, Racial differences in the availability of human leukocyte antigen-matched platelets. J. Clin. Apher 11(2), 71–77 (1996)
Article CAS PubMed Google Scholar
H. Arima, S. Iwama, H. Inaba, H. Ariyasu, N. Makita, M. Otsuki et al. Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: clinical guidelines of the Japan Endocrine Society. Endocr. J. 66(7), 581–586 (2019)
Article CAS PubMed Google Scholar
A. Imagawa, T. Hanafusa, T. Awata, H. Ikegami, Y. Uchigata, H. Osawa et al. Report of the Committee of the Japan Diabetes society on the research of fulminant and acute-onset type 1 diabetes mellitus: new diagnostic criteria of fulminant type 1 diabetes mellitus (2012). J. Diabetes Investig 3(6), 536–539 (2012)
Article PubMed PubMed Central Google Scholar
N. Ikeda, H. Kojima, M. Nishikawa, K. Hayashi, T. Futagami, T. Tsujino et al. Determination of HLA-A, -C, -B, -DRB1 allele and haplotype frequency in Japanese population based on family study. Tissue Antigens 85(4), 252–259 (2015)
Article CAS PubMed PubMed Central Google Scholar
J.M. Wenzlau, K. Juhl, L. Yu, O. Moua, S.A. Sarkar, P. Gottlieb et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc. Natl. Acad. Sci. USA. 104(43), 17040–17045 (2007)
Article CAS PubMed PubMed Central Google Scholar
Lo, V. Preiato, S. Salvagni, C. Ricci, A. Ardizzoni, U. Pagotto, C. Pelusi, Diabetes mellitus induced by immune checkpoint inhibitors: type 1 diabetes variant or new clinical entity? Review of the literature. Rev Endocr Metab Disord 22(2), 337–349 (2021)
J.M.K. de Filette, J.J. Pen, L. Decoster, T. Vissers, B. Bravenboer, B.J. Van der Auwera et al. Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review. Eur. J. Endocrinol 181(3), 363–374 (2019)
Article PubMed PubMed Central Google Scholar
Y. Shi, M. Shen, X. Zheng, Y. Chen, R. Zhao, Y. Gu et al. ICPis-induced autoimmune polyendocrine syndrome type 2: a review of the literature and a protocol for optimal management. J. Clin. Endocrinol. Metab. 105(12), e4208–e4218 (2020)
H. Inaba, Y. Kaido, S. Ito, T. Hirobata, G. Inoue, T. Sugita et al. Human leukocyte antigens and biomarkers in type 1 diabetes mellitus induced by immune-checkpoint inhibitors. Endocrinol. Metab. (Seoul). 37(1), 84–95 (2022)
Article CAS PubMed PubMed Central Google Scholar
K. Hamaguchi, A. Kimura, N. Seki, T. Higuchi, S. Yasunaga, M. Takahashi et al. Analysis of tumor necrosis factor-alpha promoter polymorphism in type 1 diabetes: HLA-B and -DRB1 alleles are primarily associated with the disease in Japanese. Tissue Antigens 55(1), 10–16 (2000)
Article CAS PubMed Google Scholar
I. Les, M. Martínez, I. Pérez-Francisco, M. Cabero, L. Teijeira, V. Arrazubi et al. Predictive biomarkers for checkpoint inhibitor immune-related adverse events. Cancers (Basel). 15(5), 1629 (2023)
Article CAS PubMed PubMed Central Google Scholar
Hasan, O. Ali, F. Berner, D. Bomze, M. Fässler, S. Diem, A. Cozzio et al. Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors. Eur. J. Cancer 107, 8–14 (2019)
L.C. Cappelli, M.T. Dorak, M.P. Bettinotti, C.O. Bingham, A.A. Shah, Association of HLA-DRB1 shared epitope alleles and immune checkpoint inhibitor-induced inflammatory arthritis. Rheumatology (Oxford) 58(3), 476–480 (2019)
留言 (0)